Background: Hypersensitivity is a well-known complication of the platinum agents cisplatin and carboplatin. Although hypersensitivity to oxaliplatin has been noted, the incidence varies significantly in reports. Risk factors for developing reactions specifically to oxaliplatin have not been evaluated. We report the 5-year incidence of hypersensitivity to oxaliplatin in our clinical program, the patient and disease characteristics associated with its occurrence, and review the literature. Methods: Clinical information on all patients treated with oxaliplatin between September 2002 and August 2007 was retrospectively reviewed. Data from patients who experienced hypersensitivity were compared to patients treated with this agent who did not. Risk factors investigated included age, sex, diagnosis, disease stage, presence of preexisting allergies, chemotherapy received, and use of oxaliplatin in front-line versus salvage therapy. Results: 247 patients received oxaliplatin, with 29 experiencing hypersensitivity, for an incidence of 11.7% (95% CI 7.7–15.8). Grade 3/4 events occurred in 1.6%. Hypersensitivity was associated with younger mean age (54.9 ± 12.5 vs. 60.4 ± 12.4 years with reactions vs. those without, p = 0.02), female gender (17.2% of females vs. 6.4% of males, p = 0.01) and with use of oxaliplatin as salvage therapy (23.9% second-line or higher vs. 9.1% front-line, p = 0.01). Conclusions: Our data demonstrate an incidence of hypersensitivity to oxaliplatin of 11.7%, with grade 3/4 events in 1.6%. As use of this agent becomes more widespread, increased vigilance for this potentially serious complication should be high, especially amongst younger patients, females, and with the use of oxaliplatin as salvage therapy; three newly recognized potential risk factors.

Keywords:
Oxaliplatin, Hypersensitivity, Neurotoxicity, Myelosuppression
1.
Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573–584.
2.
Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski JM: DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 2003;66:225–237.
3.
Gowda A, Goel R, Berdzik J, Leichman CG, Javle M: Hypersensitivity reactions to oxaliplatin: incidence and management. Oncology (Williston Park) 2004;18:1671–1675; discussion 76, 80, 83–84.
4.
Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343–2351.
5.
Gamelin L, Capitain O, Morel A, Dumont A, Traore S, Anne le B, Gilles S, Boisdron-Celle M, Gamelin E: Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 2007;13:6359–6368.
6.
Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD 3rd, Colman LK, Lanier KS, Pajon ER Jr, Cella D, Smith RE, O’Connell MJ, Costantino JP, Wolmark N: Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007;25:2205–2211.
7.
Shepherd GM: Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003;24:253–262.
8.
Lee MY, Yang MH, Liu JH, Yen CC, Lin PC, Teng HW, Wang WS, Chiou TJ, Chen PM: Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer 2007;15:89–93.
9.
Heywood GR, Rosenberg SA, Weber JS: Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin 2. J Natl Cancer Inst 1995;87:915–922.
10.
Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, Belinson J: Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999;17:1141.
11.
Markman M: Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf 2003;2:597–607.
12.
Thomas RR, Quinn MG, Schuler B, Grem JL: Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2003;97:2301–2307.
13.
Dold F, Hoey D, Carberry M, Musket A, Friedberg V, Mitchell E: Hypersensitivity in patients with metastatic colorectal carcinoma undergoing chemotherapy with oxaliplatin (abstract). Proc Am Soc Clin Oncol 2002;21:370a.
14.
Brandi G, Pantaleo MA, Galli C, Falcone A, Antonuzzo A, Mordenti P, Di Marco MC, Biasco G: Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 2003;89:477–481.
15.
Lenz G, Hacker UT, Kern W, Schalhorn A, Hiddemann W: Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution. Anticancer Drugs 2003;14:731–733.
16.
Hsuen Lim E, Seng Cheong Lim R, Seng Wu T, Loong Kong H: Oxaliplatin/fluorouracil/leucovorin in advanced colorectal carcinoma: an Asian experience. Ann Pharmacother 2003;37:1909–1912.
17.
Siu SW, Chan RT, Au GK: Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 2006;17:259–261.
18.
Escalante C, Oh JH, Baum DD, Mante M, Zalpour A, Spivey S, Stewart C, Ensor J, Grover T, Freedman R: Immediate adverse reactions to chemotherapy: experience of a large ambulatory treatment center (abstract). Proc Am Soc Clin Oncol 2006;24:8558.
19.
Markman M, Zanotti K, Kulp B, Peterson G, Markman M: Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity. Gynecol Oncol 2003;89:514–516.
20.
Maindrault-Goebel F, Andre T, Tournigand C, Louvet C, Perez-Staub N, Zeghib N, De Gramont A: Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 2005;41:2262–2267.
21.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thunn M: Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
22.
Lieberman PL (ed): Anaphylaxis and Anaphylactoid Reactions, ed 6. St. Louis, Mosby, 2003.
23.
Kitada N, Dan T, Takara K, Tsuji T, Yamasaki H, Yokoyama T, Watari M: Oxaliplatin-induced hypersensitivity reaction displaying marked elevation of immunoglobulin E. J Oncol Pharm Pract 2007;13:233–235.
24.
Medioni J, Coulon MA, Morere JF, Hennebelle F, Piperno-Neumann S, Breau JL: Anaphylaxis after oxaliplatin. Ann Oncol 1999;10:610.
25.
Santini D, Tonini G, Salerno A, Vincenzi B, Patti G, Battistoni F, Dicuonzo G, Labianca R: Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol 2001;12:132–133.
26.
Tonini G, Santini D, Vincenzi B, Borzomati D, Dicuonzo G, La Cesa A, Onori N, Coppola R: Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients. J Biol Regul Homeost Agents 2002;16:105–109.
27.
Saif MW: Hypersensitivity reactions associated with oxaliplatin. Expert Opin Drug Saf 2006;5:687–694.
28.
Polyzos A, Tsavaris N, Kosmas C, Arnaouti T, Kalahanis N, Tsigris C, Giannopoulos A, Karatzas G, Giannikos L, Sfikakis PP: Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 2001;61:129–133.
29.
Gammon D, Bhargava P, McCormick MJ: Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist 2004;9:546–549.
30.
Edmondson DA, Gruling BJ, Urmanski AM, Wong SJ, Levy MB: Oxaliplatin hypersensitivity: case report and successful repeat desensitization. Am J Ther 2007;14:116–118.
31.
Meyer L, Zuberbier T, Worm M, Oettle H, Riess H: Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 2002;20:1146–1147.
32.
Gonzalez-Mahave I, Lobera Iabairu T, Blasco Sarramian A, del Pozo Gil MD, Zorrilla M, Velez de Mendizabal E: Anaphylaxis produced by oxaliplatin. J Investig Allergol Clin Immunol 2005;15:75–77.
33.
Herrero T, Tornero P, Infante S, Fuentes V, Sanchez MN, De Barrio M, Baeza ML: Diagnosis and management of hypersensitivity reactions caused by oxaliplatin. J Investig Allergol Clin Immunol 2006;16:327–330.
34.
Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andre T, Tabah-Fisch I, de Gramont A: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR study. J Clin Oncol 2006;24:394–400.
35.
Tournigand C, Maindrault-Goebel F, Louvet C, de Gramont A, Krulik M: Severe anaphylactic reactions to oxaliplatin. Eur J Cancer 1998;34:1297–1298.
36.
Sagawa T, Sato Y, Abe S, Okuda T, Araki N, Takahari D, Okamoto T, Takayama T, Kato J, Niitsu Y: Anaphylactic reaction to oxaliplatin – a case of colon cancer (in Japanese). Gan To Kagaku Ryoho 2006;33:2093–2096.
37.
Larzilliere I, Brandissou S, Breton P, Lingoungou A, Gargot D, Ramain JP, Harnois C: Anaphylactic reaction to oxaliplatin: a case report. Am J Gastroenterol 1999;94:3387–3388.
38.
Alliot C, Messouak D, Beets C, Rapin JP: Severe anaphylactic reaction to oxaliplatin. Clin Oncol (R Coll Radiol) 2001;13:236.
39.
Schull B, Kornek GV, Scheithauer W: Idiosyncratic reaction after oxaliplatin: circumvention by use of a continuous infusional administration schedule. Ann Oncol 2001;12:1653–1654.
40.
Ng CV: Hypersensitivity reactions to oxaliplatin in two Asian patients. Ann Pharmacother 2005;39:1114–1118.
41.
Mis L, Fernando NH, Hurwitz HI, Morse MA: Successful desensitization to oxaliplatin. Ann Pharmacother 2005;39:966–969.
42.
Lim KH, Huang MJ, Lin HC, Su YW, Chang YF, Lin J, Chang MC, Hsieh RK: Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule. Anticancer Drugs 2004;15:605–607.
43.
Bhargava P, Gammon D, McCormick MJ: Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2004;100:211–212.
44.
Stahl M, Koster W, Wilke H: Reaction after oxaliplatin – prevention with corticosteroids? Ann Oncol 2001;12:874.
45.
Saif MW, Roy S, Ledbetter L, Madison J, Syrigos K: Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer oxaliplatin-induced hypersensitivity reaction. World J Gastroenterol 2007;13:5277–5281.
46.
de Vries RS, Mattijssen EJ, van Sorge AA: Serious delayed hypersensitivity reaction to oxaliplatin. Ann Oncol 2006;17:1723–1724.
47.
Carteni G, Fiorentino R, Vecchione L, Chiurazzi B, Battista C: Panitumumab a novel drug in cancer treatment. Ann Oncol 2007;18(suppl 6):vi16–vi21.
48.
Giusti RM, Shastri K, Pilaro AM, Fuchs C, Cordoba-Rodriguez R, Koti K, Rothmann M, Men AY, Zhao H, Hughes M, Keegan P, Weiss KD, Pazdur R: U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 2008;14:1296–1302.
49.
Jean GW, Shah SR: Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy 2008;28:742–754.
50.
Garufi C, Cristaudo A, Vanni B, Bria E, Aschelter AM, Santucci B, Terzoli E: Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol 2003;14:497–498.
51.
Rosique-Robles D, Vicent Verge JM, Borras-Blasco J, Giner-Marco V, Castera E, Galan-Brotons A, Abad J: Successful desensitization protocol for hypersensitivity reactions caused by oxaliplatin. Int J Clin Pharmacol Ther 2007;45:606–610.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.